|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singal AG, Pillai A and Tiro J: Early
detection, curative treatment, and survival rates for
hepatocellular carcinoma surveillance in patients with cirrhosis: A
meta-analysis. PLoS Med. 11:e10016242014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parikh ND, Tayob N and Singal AG:
Blood-based biomarkers for hepatocellular carcinoma screening:
Approaching the end of the ultrasound era? J Hepatol. 78:207–216.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Schwartz M and Mazzaferro V:
Resection and liver transplantation for hepatocellular carcinoma.
Semin Liver Dis. 25:181–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao YY, Takahashi M, Gu JG, Miyoshi E,
Matsumoto A, Kitazume S and Taniguchi N: Functional roles of
N-glycans in cell signaling and cell adhesion in cancer. Cancer
Sci. 99:1304–1310. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Taylor M and Drickamer K: Introduction to
Glycobiology. Oxford (England): Oxford University Press; pp.
250–256. 2011
|
|
8
|
Taniguchi N and Kizuka Y: Glycans and
cancer: Role of N-glycans in cancer biomarker, progression and
metastasis, and therapeutics. Adv Cancer Res. 126:11–51. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verhelst X, Vanderschaeghe D, Castéra L,
Raes T, Geerts A, Francoz C, Colman R, Durand F, Callewaert N and
Van Vlierberghe H: A glycomics-based test predicts the development
of hepatocellular carcinoma in cirrhosis. Clin Cancer Res.
23:2750–2758. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mak LY, To WP, Wong DK, Fung J, Liu F,
Seto WK, Lai CL and Yuen MF: Serum Mac-2 binding protein
glycosylation isomer level predicts hepatocellular carcinoma
development in E-negative chronic hepatitis B patients. World J
Gastroenterol. 25:1398–1408. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mak LY, Ko M, To E, Wong DK, Ma JH, Hui
TL, Seto WK, Fung J, Lai CL and Yuen MF: Serum Mac-2-binding
protein glycosylation isomer and risk of hepatocellular carcinoma
in entecavir-treated chronic hepatitis B patients. J Gastroenterol
Hepatol. 34:1817–1823. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tseng TC, Peng CY, Hsu YC, Su TH, Wang CC,
Liu CJ, Yang HC, Yang WT, Lin CH, Yu ML, et al: Baseline Mac-2
binding protein glycosylation isomer level stratifies risks of
hepatocellular carcinoma in chronic hepatitis b patients with oral
antiviral therapy. Liver Cancer. 9:207–220. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heo JY, Kim SU, Kim BK, Park JY, Kim DY,
Ahn SH, Park YN, Ahn SS, Han KH and Kim HS: Use of Wisteria
Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in
Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B
Virus. Medicine (Baltimore). 95:e33282016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawaguchi K, Honda M, Otha H, Terashima T,
Shimakami T, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi
E, et al: Serum Wisteria floribunda agglutinin-positive Mac-2
binding protein predicts hepatocellular carcinoma incidence and
recurrence in nucleos(t)ide analogue therapy for chronic hepatitis
B. J Gastroenterol. 53:740–751. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Hu HH, Lee MH, Korenaga M, Jen CL,
Batrla-Utermann R, Lu SN, Wang LY, Mizokami M, Chen CJ and Yang HI:
Serum Levels of M2BPGi as short-term predictors of hepatocellular
carcinoma in untreated chronic hepatitis B patients. Sci Rep.
7:143522017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML,
Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, et al: Mac-2 binding
protein glycosylation isomer as a hepatocellular carcinoma marker
in patients with chronic hepatitis B or C Infection. Hepatol
Commun. 3:493–503. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Su TH, Peng CY, Tseng TC, Yang HC, Liu CJ,
Liu CH, Chen PJ, Chen DS and Kao JH: Serum Mac-2-Binding protein
glycosylation isomer at virological remission predicts
hepatocellular carcinoma and death in chronic hepatitis B-Related
cirrhosis. J Infect Dis. 221:589–597. 2020.PubMed/NCBI
|
|
18
|
Murata A, Amano N, Sato S, Tsuzura H,
Tomishima K, Sato S, Matsumoto K, Shimada Y, Iijima K and Genda T:
On-treatment Serum Mac-2 binding protein glycosylation isomer
(M2BPGi) Level and risk of hepatocellular carcinoma development in
patients with chronic hepatitis B during Nucleot(s)ide analogue
therapy. Int J Mol Sci. 21:20512020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shinkai N, Nojima M, Lio E, Matsunami K,
Toyoda H, Murakami S, Inoue T, Ogawa S, Kumada T and Tanaka Y: High
levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi)
predict the development of hepatocellular carcinoma in hepatitis B
patients treated with nucleot(s)ide analogues. J Gastroenterol.
53:883–889. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim HS, Kim SU, Kim BK, Park JY, Kim DY,
Ahn SH, Han KH, Park YN, Han DH, Kim KS, et al: Serum Wisteria
floribunda agglutinin-positive human Mac-2 binding protein level
predicts recurrence of hepatitis B virus-related hepatocellular
carcinoma after curative resection. Clin Mol Hepatol. 26:33–44.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin YJ, Chang CL, Chen LC, Hu HH, Liu J,
Korenaga M, Huang YH, Jen CL, Su CY, Nishida N, et al: A
glycomarker for short-term prediction of hepatocellular carcinoma:
A longitudinal study with serial measurements. Clin Trans
Gastroenterol. 9:1832018. View Article : Google Scholar
|
|
22
|
Yamasaki K, Tateyama M, Abiru S, Komori A,
Nagaoka S, Saeki A, Hashimoto S, Sasaki R, Bekki S, Kugiyama Y, et
al: Elevated serum levels of wisteria floribunda
agglutinin-positive human Mac-2 binding protein predict the
development of hepatocellular carcinoma in hepatitis C patients.
Hepatology. 60:1563–1570. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Inoue T, Tsuzuki Y, Lio E, Shinkai N,
Matsunami K, Fujiwara K, Matsuura K, Nojiri S and Tanaka Y:
Clinical evaluation of hepatocarcinogenesis and outcome using a
novel glycobiomarker wisteria floribunda agglutinin-positive Mac-2
Binding Protein (WFA+-M2BP) in Chronic Hepatitis C with Advanced
Fibrosis. Jpn J Infect Dis. 71:177–183. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakagawa M, Nawa N, Takeichi E, Shimizu T,
Tsuchiya J, Sato A, Miyoshi M, Kawai-Kitahata F, Murakawa M, Nitta
S, et al: Mac-2 binding protein glycosylation isomer as a novel
predictive biomarker for patient survival after hepatitis C virus
eradication by DAAs. J Gastroenterol. 55:990–999. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sasaki R, Yamasaki K, Abiru S, Komori A,
Nagaoka S, Saeki A, Hashimoto S, Bekki S, Kugiyama Y, Kuno A, et
al: Serum wisteria floribunda agglutinin-positive Mac-2 binding
protein values predict the development of hepatocellular carcinoma
among patients with chronic hepatitis c after sustained virological
response. PLoS One. 10:e01290532015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagata H, Nakagawa M, Nishimura-Sakurai Y,
Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Goto F, Otani S,
Kawai-Kitahata F, et al: Serial measurement of Wisteria floribunda
agglutinin positive Mac-2-binding protein is useful for predicting
liver fibrosis and the development of hepatocellular carcinoma in
chronic hepatitis C patients treated with IFN-based and IFN-free
therapy. Hepatol Int. 10:956–964. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fujiyoshi M, Kuno A, Gotoh M, Fukai M,
Yokoo H, Kamachi H, Kamiyama T, Korenaga M, Mizokami M, Narimatsu
H, et al: Clinicopathological characteristics and diagnostic
performance of Wisteria floribunda agglutinin positive
Mac-2-binding protein as a preoperative serum marker of liver
fibrosis in hepatocellular carcinoma. J Gastroenterol.
50:1134–1144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Toyoda H, Kumada T, Tada T, Kaneoka Y,
Maeda A, Korenaga M, Mizokami M and Narimatsu H: Serum WFA+-M2BP
levels as a prognostic factor in patients with early hepatocellular
carcinoma undergoing curative resection. Liver int. 36:293–301.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mak LY, Wong DK, Cheung KS, Seto WK, Lai
CL and Yuen MF: Role of serum M2BPGi levels on diagnosing
significant liver fibrosis and cirrhosis in treated patients with
chronic hepatitis B virus infection. Clin Transl Gastroenterol.
9:1632018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matsumae T, Kodama T, Tahata Y, Myojin Y,
Doi A, Nishio A, Yamada R, Nozaki Y, Oshita M, Hiramatsu N, et al:
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular
Carcinoma after Hepatitis C Virus Elimination by Direct-Acting
Antiviral. Cancers (Basel). 15:4632023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Asazawa H, Kamada Y, Takeda Y, Takamatsu
S, Shinzaki S, Kim Y, Nezu R, Kuzushita N, Mita E, Kato M and
Miyoshi E: Serum fucosylated haptoglobin in chronic liver diseases
as a potential biomarker of hepatocellular carcinoma development.
Clin Chem Lab Med. 53:95–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang C, Fang M, Feng H, Liu L, Li Y, Xu
X, Wang H, Wang Y, Tong L, Zhou L and Gao C: N-glycan fingerprint
predicts alpha-fetoprotein negative hepatocellular carcinoma: A
large-scale multicenter study. Int J Cancer. 149:717–727. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aoyagi Y, Isokawa O, Suda T, Watanabe M,
Suzuki Y and Asakura H: The Fucosylation Index of a-Fetoprotein as
a possible prognostic indicator for patients with hepatocellular
carcinoma. Cancer. 83:2076–2082. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nouso K, Kobayashi Y, Nakamura S,
Kobayashi S, Takayama H, Toshimori J, Kuwaki K, Hagihara H, Onishi
H, Miyake Y, et al: Prognostic importance of fucosylated
alpha-fetoprotein in hepatocellular carcinoma patients with low
alpha-fetoprotein. J Gastroenterol Hepatol. 26:1195–1200. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lio E, Ocho M, Togayachi A, Nojima M, Kuno
A, Ikehara Y, Hasegawa I, Yatsuhashi H, Yamasaki K, Shimada N, et
al: A novel glycobiomarker, Wisteria floribunda agglutinin
macrophage colony-stimulating factor receptor, for predicting
carcinogenesis of liver cirrhosis. Int J Cancer. 138:1462–1471.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fang M, Zhao YP, Zhou FG, Lu LG, Qi P,
Wang H, Zhou K, Sun SH, Chen CY and Gao CF: N-glycan based models
improve diagnostic efficacies in hepatitis B virus-related
hepatocellular carcinoma. Int J Cancer. 127:148–159. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li L, Gu X, Fang M, Ji J, Yi C and Gao C:
The diagnostic value of serum fucosylated fetuin A in hepatitis B
virus-related liver diseases. Clin Chem Lab Med. 54:693–701. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yi CH, Weng HL, Zhou FG, Fang M, Ji J,
Cheng C, Wang H, Liebe R, Dooley S and Gao CF: Elevated
core-fucosylated IgG is a new marker for hepatitis B virus-related
hepatocellular carcinoma. Oncoimmunology. 4:e10115032015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tamaki N, Kuno A, Matsuda A, Tsujikawa H,
Yamazaki K, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Korenaga
M, et al: Serum wisteria floribunda agglutinin-positive sialylated
mucin 1 as a marker of progenitor/biliary features in
hepatocellular carcinoma. Sci Rep. 7:2442017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kuno A, Ikehara Y, Tanaka Y, Ito K,
Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M and
Narimatsu H: A serum ‘sweet-doughnut’ protein facilitates fibrosis
evaluation and therapy assessment in patients with viral hepatitis.
Sci Rep. 3:10652013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim TH, Kim SY, Tang A and Lee JM:
Comparison of international guidelines for noninvasive diagnosis of
hepatocellular carcinoma: 2018 update. Clin Mol Hepatol.
25:245–263. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Korean Liver Cancer Study Group (KLCSG);
National Cancer Center and Korea (NCC), . 2014 Korean Liver Cancer
Study Group-National Cancer Center Korea practice guideline for the
management of hepatocellular carcinoma. Korean J Radiol.
16:465–522. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hashimoto K, Nishimura S, Shinyashiki Y,
Ito T and Akagi M: Characterizing inflammatory markers in highly
aggressive soft tissue sarcomas. Medicine (Baltimore).
101:e306882022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Peng X, Gong C, Zhang W and Zhou A:
Advanced development of biomarkers for immunotherapy in
hepatocellular carcinoma. Front Oncol. 12:10910882023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vajaria BN and Patel PS: Glycosylation: A
hallmark of cancer? Glycoconj J. 34:147–156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yilma M, Saxena V and Mehta N: Models to
predict development or recurence of hepatocellular carcinoma (HCC)
in patients with advanced hepatic fibrosis. Curr Gastroenterol Rep.
24:1–9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Keeley TS, Yang S and Lau E: The diverse
contributions of fucose linkages in cancer. Cancers (Basel).
11:12412019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yin X, Rana K, Ponmudi V and King MR:
Knockdown of fucosyltransferase III disrupts the adhesion of
circulating cancer cells to E-selectin without a ecting
hematopoietic cell adhesion. Carbohydr Res. 345:2334–2342. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Berhane S, Toyoda H, Tada T, Kumada T,
Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP,
Benckert J, et al: Role of the GALAD and BALAD-2 serological models
in diagnosis of hepatocellular carcinoma and prediction of survival
in patients. Clin Gastroenterol Hepatol. 14:875–886.e6. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Toyoda H, Kumada T, Kaneoka Y, Osaki Y,
Kimura T, Arimoto A, Oka H, Yamazaki O, Manabe T, Urano F, et al:
Prognostic value of pretreatment levels of tumor markers for
hepatocellular carcinoma on survival after curative treatment of
patients with HCC. J Hepatol. 49:223–232. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kotwani P, Chan W, Yao F and Mehta N: DCP
and AFP-L3 are complementary to AFP in predicting high-risk explant
features: Results of a prospective study. Clin Gastroenterol
Hepatol. 20:701–703.e2. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Samman BS, Hussein A, Samman RS and
Alharbi AS: Common sensitive diagnostic and prognostic markers in
hepatocellular carcinoma and their clinical significance: A review.
Cureus. 14:e239522022.PubMed/NCBI
|
|
53
|
Witarto AP, Witarto BS, Pramudito SL,
Putra AJE, Nurhadi GM and Maimunah U: Baseline serum Mac-2 binding
protein glycosylation isomer as a predictor of hepatocellular
carcinoma in chronic hepatitis B patients: A systematic review and
meta-analysis. Ann Gastroenterol. 35:627–639. 2022.PubMed/NCBI
|
